Tim Franklin, ImmuPharma’s Chief Operating Officer talks to Proactive Investor on the forthcoming meeting in December between the Company’s partner Avion and the FDA, to discuss the international Phase 3 Lupus clinical trial – 25th November 2020

26th November 2020 - 12:30 pm

Dr Franklin says at the meeting, Avion together with the FDA will discuss key points and following the meeting the FDA will respond giving their guidance.

He says a conditional approval would allow the marketing of Lupuzor™ prior to the completion of the new Phase 3, based on the clinically significant data previously generated in the completed Phase 2 and 3 clinical trials to date.

Share this article